Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET® program in autoimmune indications, and more
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi.
As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 of issue premium).
The subscription price of €1.7974 per share (€0.05 in nominal amount and €1.7474 of issue premium) is equal to the daily volume-weighted average price of the ordinary shares of Innate on the regulated market of Euronext in Paris on April 23, 2025.
“We welcome Sanofi’s strategic investment in Innate, which further reinforces the strength of our collaboration. The proceeds from this capital increase will be used for general corporate purposes, including extending our cash runway to support continued pipeline execution and long-term value creation,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma.
This capital increase is to be completed pursuant to the 22nd resolution of the combined general meeting of shareholders of Innate held on 23 May 2024.
Closing of the capital increase is expected to take place on April 25, 2025. The newly issued shares will be admitted to trading on the regulated market of Euronext in Paris on the same day.
The tables below set out the Company’s shareholding, based on the information available to Innate as of the date of this press release, before and after the closing of the capital increase:
Before closing
Shareholder | Nb of Shares1 | % | Nb of voting rights2 | % |
Novo Nordisk A/S | 9,817,546 | 11.71% | 9,817,546 | 11.60% |
Medimmune Limited | 7,485,500 | 8.93% | 7,485,500 | 8.85% |
Bpifrance Participations | 6,389,406 | 7.62% | 6,389,406 | 7.55% |
Members of the Executive Board, Supervisory Board and Leadership Team | 846,944 | 1.01% | 911,444 | 1.08% |
Treasury shares | 18,575 | 0.02% | 0 | 0% |
Public | 59,286,440 | 70.71% | 59,995,085 | 70.92% |
Total | 83,844,411 | 100% | 84,598,981 | 100% |
After closing
Shareholder | Nb of Shares1 | % | Nb of voting rights2 | % |
Novo Nordisk A/S | 9,817,546 | 10.65% | 9,817,546 | 10.56% |
Sanofi-Aventis Participations | 8,345,387 | 9.05% | 8,345,387 | 8.98% |
Medimmune Limited | 7,485,500 | 8.12% | 7,485,500 | 8.05% |
Bpifrance Participations | 6,389,406 | 6.93% | 6,389,406 | 6.87% |
Members of the Executive Board, Supervisory Board and Leadership Team | 846,944 | 0.92% | 911,444 | 0.98% |
Treasury shares | 18,575 | 0.02% | 0 | 0% |
Public | 59,286,440 | 64.31% | 59,995,085 | 64.55% |
Total | 92,189,798 | 100% | 92,944,368 | 100% |
1 Ordinary shares and 2016 and 2017 free preference shares
2 See Innate’s published number of shares and voting rights
| Press Release in English | 182.87 KB |
| Communiqué de presse en français | 153.6 KB |